{"id":1004483,"date":"2026-09-18T08:12:51","date_gmt":"2026-09-18T12:12:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/"},"modified":"2026-09-18T08:12:51","modified_gmt":"2026-09-18T12:12:51","slug":"corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/","title":{"rendered":"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli<\/b><sup>\u00ae<\/sup><b> (Relacorilant)<\/b><\/p>\n<p>REDWOOD CITY, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCorcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer.<\/p>\n<p>\nThe CHMP\u2019s recommendation is based on positive data from Corcept\u2019s Phase 2 and pivotal Phase 3 <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.corcept.com%2Fnews-releases%2Fnews-release-details%2Foverall-survival-primary-endpoint-met-corcepts-pivotal-phase-3&amp;esheet=54606461&amp;newsitemid=20260918490790&amp;lan=en-US&amp;anchor=ROSELLA&amp;index=1&amp;md5=bf9e3a33188799233e11279e84520bf5\">ROSELLA<\/a> trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monotherapy.<\/p>\n<p>\nThe EC will review the CHMP&#8217;s opinion and issue a final decision regarding approval in the fourth quarter of 2026.<\/p>\n<p>\n\u201cThe CHMP\u2019s positive opinion takes us a big step closer to making the benefits of glucocorticoid receptor antagonism available to patients in the EU. We look forward to the European Commission\u2019s final decision,\u201d said Joseph K. Belanoff, M.D., Corcept\u2019s Chief Executive Officer. \u201cI want to thank the CHMP for conducting such an efficient and timely review. I also want to thank the healthcare providers and patients who participated in relacorilant\u2019s clinical trials. Without them, advancing this fundamentally new approach to treating cancer would not have been possible.\u201d<\/p>\n<p><b>About Relacorilant<\/b><\/p>\n<p>\nRelacorilant achieves its effects by binding to the glucocorticoid receptor but not to the body\u2019s other hormone receptors. Relacorilant is the only selective glucocorticoid receptor modulator approved by the U.S. Food and Drug Administration for any indication. It is marketed in the United States for the treatment of patients with platinum-resistant ovarian cancer under the trade name Lifyorli<sup>\u00ae<\/sup>. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use, formulation, manufacturing and other patents.<\/p>\n<p><b>About the ROSELLA Pivotal Trial<\/b><\/p>\n<p>\nROSELLA was relacorilant\u2019s pivotal Phase 3 trial. It enrolled 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. The ROSELLA trial is being conducted in collaboration with the GOG Foundation, Inc., the European Network of Gynaecological Oncological Trial groups, the Asia-Pacific Gynecologic Oncology Trials Group, the Latin American Cooperative Oncology Group and the Australia New Zealand Gynaecological Oncology Group.<\/p>\n<p><b>About Ovarian Cancer<\/b><\/p>\n<p>\nOvarian cancer is the fifth most common cause of cancer death in women. Patients with disease that progresses less than six months after commencing platinum-based chemotherapy have \u201cplatinum-resistant\u201d disease. There are few treatment options for these women. Approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year in the United States, with at least an equal number in Europe.<\/p>\n<p><b>About Cortisol&#8217;s Role in Oncology<\/b><\/p>\n<p>\nCortisol plays a role in tumor growth through several mechanisms. It helps solid tumors resist chemotherapy by inhibiting cellular apoptosis \u2014 the tumor-killing effect chemotherapy is meant to stimulate. In some cancers, cortisol promotes tumor growth by activating oncogenic signaling in the cells to which it binds. Cortisol also suppresses the body&#8217;s immune response, which weakens its ability to fight all diseases, including cancer.<\/p>\n<p><b>About Corcept Therapeutics<\/b><\/p>\n<p>\nFor over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced development programs in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nStatements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements.<\/p>\n<p>\nIn this press release, forward-looking statements include statements concerning: relacorilant\u2019s safety profile and potential as a treatment for patients with platinum-resistant ovarian cancer; the anticipated timing and outcome of the EC\u2019s review of the CHMP opinion, including the potential for the EC to approve our marketing application in the fourth quarter of 2026; and Corcept\u2019s intent to make the benefits of glucocorticoid receptor antagonism available to patients in the EU.<\/p>\n<p>\nA further description of risks and uncertainties affecting our forward-looking statements can be found in our SEC filings, which are available at our website and the SEC\u2019s website. These risks and uncertainties include, but are not limited to, those related to: our ability to operate our business; our efforts to study and develop Korlym, Lifyorli, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules\u2019 clinical attributes; regulatory approvals, mandates, oversight and other requirements imposed on our products or our business by laws, regulations or discretion of government authorities; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260918490790\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260918490790\/en\/<\/a><\/span><\/p>\n<p>\nInvestor inquiries:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@corcept.com\">ir@corcept.com<br \/>\n<\/a><br \/>Media inquiries:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:communications@corcept.com\">communications@corcept.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.corcept.com%2F&amp;esheet=54606461&amp;newsitemid=20260918490790&amp;lan=en-US&amp;anchor=www.corcept.com&amp;index=2&amp;md5=69c25233059292afeda4c48975055c48\">www.corcept.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Neurology Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260918490790\/en\/2330117\/3\/Corcept_logo_new_black.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) REDWOOD CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP\u2019s recommendation is based on positive data from Corcept\u2019s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1004483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) REDWOOD CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP\u2019s recommendation is based on positive data from Corcept\u2019s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival &hellip; Continue reading &quot;Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-18T12:12:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)\",\"datePublished\":\"2026-09-18T12:12:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/\"},\"wordCount\":916,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/\",\"name\":\"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-09-18T12:12:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/","og_locale":"en_US","og_type":"article","og_title":"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) - Market Newsdesk","og_description":"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) REDWOOD CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP\u2019s recommendation is based on positive data from Corcept\u2019s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival &hellip; Continue reading \"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-18T12:12:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)","datePublished":"2026-09-18T12:12:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/"},"wordCount":916,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/","name":"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-09-18T12:12:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260918490790r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyorli-relacorilant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli\u00ae (Relacorilant)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1004483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1004483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1004483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1004483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}